Aligos Therapeutics Presents Positive Data at EASL Congress 2026; HOLD Stance Unchanged

What happened

Aligos Therapeutics presented positive data from ten studies at the EASL Congress 2026, covering its three lead assets: ALG-055009 in MASH, ALG-000184 in HBV, and ALG-097558 in coronaviruses. The data reinforce early signs of potency observed in prior studies, such as ALG-055009’s statistically significant MRI-PDFF reduction and ALG-000184’s strong viral suppression. However, the DeepValue Master Report's HOLD stance remains unchanged due to the early stage of these programs and the need for more definitive Phase 2b results, particularly for ALG-055009. The company's improved liquidity of $122.9M provides at least 12 months of runway, but near-term value hinges on executing histology-based trials and securing non-dilutive partnerships. The positive data are consistent with the existing thesis and do not materially alter the risk/reward balance.

Implication

The EASL data are incrementally positive, confirming preclinical promise and Phase 2a results, which is consistent with the DeepValue report's assessment of upside optionality. However, the data do not de-risk the critical histology-based Phase 2b trial for ALG-055009 or resolve the need for a partnership to fund it. The HBV and coronavirus programs also remain early, with competitive pressures in MASH (resmetirom, GLP-1s) and post-pandemic antiviral demand uncertainty. Investors should maintain a HOLD stance, awaiting clear catalysts: Phase 2b design/initiation for ALG-055009, partnering outcomes, and continued HBV program progress. The improved cash runway of $122.9M reduces near-term financing risk, but dilutive raises remain a risk if catalysts are delayed. A shift to BUY would require visible progress on these fronts, while any clinical setbacks or significant delays would support a SELL.

Thesis delta

The thesis remains unchanged: Aligos offers attractive upside optionality across three assets, but near-term value realization hinges on Phase 2b execution and partnerships in an increasingly competitive landscape. The positive EASL data confirm early signals but do not reduce the binary risks of histology-based trials or the need for non-dilutive capital. Thus, the HOLD stance is maintained, with no reason to upgrade or downgrade at this juncture.